Aims-Immunohistological and molecular characterisation ofa case ofperipheral T-cell lymphoma (PTCL) of angioimmunoblastic T-cell lymphoma (AILD) type. Methods-Frozen and paraffin wax sections of the diagnostic lymph node were stained with a panel of T-and B-cell lineage monoclonal antibodies. DNA was isolated from the paraffin wax embedded biopsy material for T-cell receptor (TCR) and immunoglobulin (Ig) PCR amplification, and resultant PCR products were cloned and sequenced. Results-Immunohistological analysis of the presenting lymph node was consistent with an extensive infiltrate ofpleomorphic CD3+CD8+ lymphocytes. Most (>80%) of these infiltrating CD3+ cells were also positive for the TCR VB5.1 gene family product, and were shown to be oligoclonal by TCRB PCR amplification and sequencing. Three oligoclones of B cells were also demonstrable by PCR amplification with Ig heavy chain primers and sequencing, a finding at variance with the diagnosis of AILD.
An 82 year old woman presented in March 1987 with a one month history of neck swelling, rashes and night sweats. Examination revealed a cervical mass and a chest x ray film revealed a widened mediastinum. A lymph node biopsy specimen was taken and the histology was consistent with a peripheral T-cell lymphoma (PTCL) of angioimmunoblastic T-cell lymphoma (AILD) type. ' At the time of diagnosis, no particular therapeutic recommendations were in force and the patient was treated with chlorambucil. Despite regression of nodal masses, the patient became leucopenic and thrombocytopenic. Chlorambucil was withdrawn but the patient's clinical condition continued to deteriorate and she died seven months after presentation.
Methods
Frozen and paraffin wax sections were stained with monoclonal antibodies including those directed against CD3, CD4, CD8, CD20, and CD79a, and KiM4B (dendritic cells), MIB1 (proliferation marker), BF1 (TCRB chain), LC4 (VB5.1), ICI (VB5.2 + 5.3), W112 (VB5.3), OT145 (VB6.7 A allele), 16G8 (VB8), and S511 (VB12.1) as described previously.' Positively stained cells were counted using a visual image display system. Monoclonal antibody directed against EpsteinBarr virus (EBV) latent membrane protein 1 (LMP-1) and in situ hybridisation (EBV polyprobe kit; Novocastra Laboratories, Newcastle upon Tyne, UK) were used to detect infected cells.
DNA was isolated from paraffin wax embedded biopsy material for TCRG, B and IgH PCR amplification and sequencing using methods described previously. 
Results
Immunohistology revealed an actively dividing CD3+, predominantly CD8+ pleomorphic T-cell population with absent B-cell follicles; about 80% of the CD3+ cell population was positive for TCR VB5. 1 (fig 1) . Immunohistol- 
Oligoclonal populations of T and B cells in angioimmunoblastic T-cell lymphoma Discussion
The immunohistology of the case described in this report was consistent with AILD with a predominant CD3+ pleomorphic cell population and a network of dendritic cells in the absence of B-cell follicles. However, a predominance of CD8+ compared with CD4+ cells was noted in contrast to other cases.' The most remarkable finding in this case was the presence of an expanded TCR VB5.1 family comprising >80% of the CD3+ population. There was no histological evidence for abnormal B cells positive for CD79a and CD20 on paraffin wax sections.
The molecular analysis of this case was complex. PCR amplification of DNA with a consensus VB primer revealed polyclonal smears on electrophoresis, whereas PCR amplification with a VB5.1 family primer identified two minor bands that, on sequencing, revealed two functional clones consistent with oligoclones among the TCR VB5.1 population. These oligoclones were not identified using the consensus VB primer owing to the lack of homology of the VB primer, which has a mismatch of three of 19 bases with the VB5. 1 family sequence.4 Analysis of TCRG PCR products revealed two bands in a polyclonal background. Both clonal rearrangements proved to be non-functional; such data are consistent with TCRAB expressing T cells. Alternatively, these non-functional rearrangements may be associated with the oligoclonal B-cell populations identified.
IgH FR2 PCR amplification revealed two clonal bands whereas sequence analysis of the IgH FR2 PCR reaction mixture revealed three functional immunoglobulin VH3 family clonal sequences; these data are consistent with oligoclonal B-cell populations rather than somatic mutations within a single tumour population.5 The molecular weights of two of the clones, as judged from sequence analysis, corresponded to the two bands demonstrated by gel electrophoresis. A third minor clone, which was not clearly visible by gel electrophoresis, was identified after sequence analysis. In a previous study, we detected oligoclones in a diffuse, high grade B-cell lymphoma3 but have never demonstrated oligoclones from PCR amplification of normal human peripheral blood. These PCR data are supportive evidence for the Tand B-cell oligoclones found in this patient.
The role of T-and B-cell oligoclones in the disease pathogenesis of this case is uncertain. The clear demonstration of oligoclonal T-cell populations by PCR amplification is suggestive of reactive rather than malignant T-cell infiltrates. Polyclonal or oligoclonal restricted T-cell family responses have also been described in autoimmune diseases' in response to superantigens and among CD3/CD8 populations in the elderly.7 Nevertheless, reports of expanded TCR V gene families in autoimmunity and in the elderly do not include aetiologies comparable with this case; and the patient did not have preexisting autoimmune disease or evidence of neutropenia or red cell aplasia which are commonly associated with clonal CD3/CD8 lymphocyte populations.8
The presence of oligoclones of B cells has not been described in B-cell non-Hodgkin lymphoma, and sequence analysis indicated the presence of different clones rather than somatic mutations within one clone. Such populations are found in EBV infiltrates although evidence of EBV infection was not found. Whether these populations represent neoplastic clones is not known in the absence of histological evidence for malignant B cells associated with T-cell-rich B-cell lymphoma. It is conceivable that these B-cell populations elicited an oligoclonal T-cell response as restricted TCR V gene family responses have been described in B-cell chronic lymphocytic leukaemia and myeloma.' Indeed, we have recently described an oligoclonal VB5. 1 population in an immunoblastic B-cell lymphoma. 3 In summary, a case of histologically defined PTCL is described in which, on molecular analysis, both T-and B-cell oligoclones were detected in the presence of a predominant TCR VB5.1 T-cell family. In the absence of functional studies, the relation between the Tand B-cell oligoclones in this case is open to speculation. These T-cell responses may be recognising shared tumour antigens or tumour related antigens. In the case described here, B-cell oligoclones in the biopsy specimen may be presenting antigens that elicit such a T-cell response. Alternatively, the sustained T-cell response may be the result of cytokine networks described in patients with PTCL.10 This case demonstrates further the complexity and heterogeneity of this histological entity. 
